Gergely Szakács - Curriculum Vitae#

Higher Education

• 1997 - 2001 PhD, Semmelweis University of Medicine, Budapest, Hungary
  
• 1990 - 1996 MD, Semmelweis University of Medicine, Budapest, Hungary

Appointments / Positions

• 2020 - 2025 Chair, International PhD Program for Translational Oncology, Medical University of Vienna
  
• 2017 Professor for Chemical Safety and Cancer Prevention, Center for Cancer Research, Medical University of Vienna
  
• 2017 Principal Investigator, Institute of Molecular Life Sciences, Hungarian Research Network
  
• 2008 - 2017 Group Leader, Institute of Enzymology, Hungarian Academy of Sciences
  
• 2005 - 2008 Senior Research Fellow, Institute of Enzymology, Hungarian Academy of Sciences
  
• 2001 - 2005 Postdoctoral Fellow at the Laboratory of Cell Biology (LCB), National Cancer Institute, National Institutes of Health (Dr. Michael Gottesman)

Research Interests and achievements

My group is working in the field of multidrug resistance, focusing on innovative solutions to combat therapy resistant cancer. For many years, our research focused on membrane transporters, focusing on the molecular mechanism of drug efflux mediated by P-glycoprotein, and the role of the ABC transporters in multidrug resistance (MDR). Since our discovery of “MDR-selective” compounds, our aim has been to target the collateral sensitivity of drug resistant cancer cells. My research on the “Achilles’ heel” of MDR cancer was supported by an ERC Starting grant in 2012. Recently, the scope of our research has increased to include therapy resistance mechanisms linked to drug tolerant persister cells (DTPs) in breast cancer. Since joining the faculty, I established an excellence-based graduate training program at the Medical University of Vienna (FWF Doc Fund International PhD Program for Translational Oncology). From 2023, I have been the main organizer of the FEBS Advanced Course on ABC transporters.

Scientific Meetings Organized

• 2025 ABC2025 – ATP-Binding Cassette (ABC) Proteins
  
• From Multidrug Resistance to Genetic Diseases, Innsbruck, Austria
  
• 2023 9th FEBS Special Meeting on ABC Proteins, Innsbruck, Austria

Patents

• 2025 Novel anticancer therapy. EP4236917; US18281411
  
• 2017 MDR-reversing 8-hydroxy-quinoline derivatives. Patent number: 10744127

Publications

Number of papers: ~130; citations:~15K; h-index: 53
List of publications